ZONISAMIDE-13C2-15N Chemical Properties

Melting point:

158 - 160°C

storage temp. 

Refrigerator

solubility 

DMSO (Sparingly), Methanol (Slightly)

form 

Solid

color 

Off-White to Light Yellow

ZONISAMIDE-13C2-15N Usage And Synthesis

Description

Zonisamide-¹³C₂,¹⁵N is intended for use as an internal standard for the quantification of zonisamide by GC- or LC-MS. Zonisamide is an antiepileptic agent. It selectively inhibits the repeated firing of sodium channels (IC₅₀ = 2 μg/ml) in mouse embryo spinal cord neurons and inhibits spontaneous channel firing when used at concentrations greater than 10 μg/ml. In rat cerebral cortex neurons, zonisamide (1-1,000 μM) inhibits T-type calcium channels with a maximum reduction of 60% of the calcium current. Zonisamide inhibits H. pylori recombinant carbonic anhydrase (CA) and the human CA isoforms I, II, and V with K_i values of 218, 56, 35, and 21 nM, respectively. In mice, it has anticonvulsant activity against maximal electroshock seizure (MES) and pentylenetetrazole-induced maximal, but not minimal, seizures (ED₅₀s = 19.6, 9.3, and >500 mg/kg, respectively). Zonisamide (40 mg/kg, p.o.) prevents MPTP-induced decreases in the levels of dopamine , but not homovanillic acid (HVA; ) or dihydroxyphenyl acetic acid (DOPAC; ), and increases MPTP-induced decreases in the dopamine turnover rate in mouse striatum in a model of Parkinson''s disease. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

Uses

Zonisamide-13C2-15N is the labeled analogue of Zonisamide (Z700000), a sulfonamide antiseizure agent; blocks repetitive firing of voltagesensitive sodium channels and reduces voltage-sensitive T-type calcium currents. Heterocyclic methanesulfonide with anticonvulsant properties. The compound is under investigation for potential therapeutic use as an antiepileptic drug. Anticonvulsant.

References

[1] YOSHINOBU MASUDA  Masanao S  Masayuki Ishizaki. Zonisamide: Pharmacology and Clinical Efficacy in Epilepsy[J]. CNS drug reviews, 2006, 4 4: 341-360. DOI: 10.1111/j.1527-3458.1998.tb00075.x
[2] DAVID M ROCK  Charles P T  Robert L Macdonald. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant[J]. Epilepsy Research, 1989, 3 2: Pages 138-143. DOI: 10.1016/0920-1211(89)90041-7
[3] SETSUO SUZUKI. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex[J]. Epilepsy Research, 1992, 12 1: Pages 21-27. DOI: 10.1016/0920-1211(92)90087-a
[4] ISAO NISHIMORI . Carbonic anhydrase inhibitors: Cloning and sulfonamide inhibition studies of a carboxyterminal truncated α-carbonic anhydrase from Helicobacter pylori[J]. Bioorganic & Medicinal Chemistry Letters, 2006, 16 8: Pages 2182-2188. DOI: 10.1016/j.bmcl.2006.01.044
[5] GIUSEPPINA DE SIMONE . Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies[J]. Bioorganic & Medicinal Chemistry Letters, 2005, 15 9: Pages 2315-2320. DOI: 10.1016/j.bmcl.2005.03.032
[6] HAYATO YABE . Zonisamide Increases Dopamine Turnover in the Striatum of Mice and Common Marmosets Treated With MPTP[J]. Journal of pharmacological sciences, 2009, 110 1: Pages 64-68. DOI: 10.1254/jphs.09019fp

ZONISAMIDE-13C2-15N(1188265-58-8)Related Product Information

• Zonisamide-d4
• Zonisamide sodium salt
• Zonisamide-N-(6-hexanoic Acid)
• Zonisamide